<DOC>
	<DOCNO>NCT01200108</DOCNO>
	<brief_summary>The goal treatment AICS wean oral corticosteroid , i.e . reduction oral corticosteroid dose . An anticipated treatment benefit AICS reduction oral corticosteroid dose stability/improvement clinical parameter relate asthma target subject population . Ultimately , goal free subject severe asthma burden chronic oral steroid therapy .</brief_summary>
	<brief_title>AKITA Inhaled Steroid Suspension Inhalation ( AICS ) Subjects With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Written inform consent prior performance studyrelated procedure Age ≥ 18 ≤ 65 year age Diagnosis asthma ( ATS definition , either allergic nonallergic ) ≥ 6 month Asthma treat least 3 month inhale ( ICS ) oral corticosteroid ( OCS ) . Exact baseline level measure screening period subject diary entry FEV1 ≥ 40 % ≤ 79 % predict Screening Baseline Visit Documented increase FEV1 within 1530 minute use inhaled Salbutamol Screening Visit within 2 year prior Screening Mandatory usage longacting βagonists A negative pregnancy test must available woman childbearing potential screening , addition , negative urine pregnancy test must present randomization ( prior randomization one treatment group ! ) Women childbearing potential must agree use reliable method contraception screen 4 week study completion study drug discontinuation case study drug treatment stop prematurely . In study , hormonebased contraceptive alone consider reliable method History allergy adverse experience Budesonide Pregnant woman nurse mother Upper respiratory tract infection within 4 week Screening Emergency room visit treatment asthma exacerbation within 4 week Screening Hospitalization asthma within 3 month Screening Use antiIgE , methotrexate , oral gold , Dapsone , i.v . gamma globulin within 3 month Screening Treatment investigational asthma treatment within 30 day prior Screening Evidence chronic lung disease asthma , include limited : cystic fibrosis , allergic bronchopulmonary aspergillosis ( ABPA ) , COPD , chronic bronchitis emphysema History medication noncompliance History significant medical illness condition Investigator 's opinion place subject undue risk participate study Past episode anaphylaxis severe respiratory symptom Oral corticosteroid average daily dose exceed maximum amount Currently smoke history smoking ≥ 10 pack year Taking oral i.v . corticosteroid disease indication asthma Abnormal lab value chemistry test Screening may indicate impaired ability metabolize and/or excrete Budesonide ( AST , ALT &gt; 3 time upper limit normal range , serum creatinine &gt; 1.5 time upper limit normal range )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Severe Asthma , require chronic oral steroid use</keyword>
</DOC>